Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Clinical trial NCT03040973 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03040973
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-23
- Primary completion
- 2027-07-30
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.